Cancers, Vol. 12, Pages 1990: Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future
Cancers, Vol. 12, Pages 1990: Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future
Cancers doi: 10.3390/cancers12071990
Authors:
Romain Cohen
Qian Shi
Thierry André
Immune checkpoint inhibitors (ICI) have reshaped therapeutic strategies for cancer patients. The development of ICI for early stage colorectal cancer is accompanied by specific challenges: (i) the selection of patients who are likely to benefit from these treatments, i.e., patients with tumors harboring predictive factors of efficacy of ICI, such as microsatellite instability and/or mismatch repair deficiency (MSI/dMMR), or other potential parameters (increased T cell infiltration using Immunoscore® or others, high tumor mutational burden, POLE mutation), (ii) the selection of patients at risk of disease recurrence (poor prognostic features), and (iii) the choice of an accurate clinical trial methodological framework. In this review, we will discuss the ins and outs of clinical research of ICI for early stage MSI/dMMR CC patients in adjuvant and neoadjuvant settings. We will then summarize data that might support the development of ICI in localized colorectal cancer beyond MSI/dMMR.
Source: Cancers - Category: Cancer & Oncology Authors: Romain Cohen Qian Shi Thierry Andr é Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | Gastroschisis Repair | Immunotherapy | Neoadjuvant Therapy